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Virus-based cancer vaccines are nowadays considered an interesting approach in the ﬁeld of
cancer immunotherapy, despite the observation that the majority of the immune responses
they elicit are against the virus and not against the tumor. In contrast, targeting tumor
associated antigens is effective, however the identiﬁcation of these antigens remains
challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an
oncolytic virus artiﬁcially wrapped with tumor cancer membranes carrying tumor antigens.
We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro
and in vivo. We show that this nanoparticle platform controls the growth of aggressive
melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a
highly speciﬁc anti-cancer immune response. In conclusion, ExtraCRAd might serve as the
next generation of personalized cancer vaccines with enhanced features over standard
vaccination regimens, representing an alternative way to target cancer.
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In the last decade, research on cancer immunotherapy resultedin a new set of potential treatments with promising results inthe clinics1. Among these, immune check-point inhibitors are
one of the few immunotherapies that have been clinically vali-
dated, yet with variable results, ranging from complete responses
to hyperprogression2–4.
Among the different experimental treatments, active cancer
immunotherapy and, more speciﬁcally, viral therapy hold great
promises for the future5,6. Theoretically, tumor lysate can elicit
anti-tumor activity by presenting the immune system with a wide
range of tumor-associated antigens (TAAs) and neoantigens for
immune system processing7. Unfortunately, when tumor lysate
lacks a proper stimulation, it could drive to tolerance by the
immune system, resulting in an ineffective approach8.
Conversely, viruses are recognized as non-self, thereby leading
to the initiation of an immune response due to their natural
adjuvant properties9. These attributes can be exploited in cancer
immunotherapy by the use of oncolytic viruses, which are viruses
that, by design, only replicate in cancer cells, while leaving the
healthy cells unharmed. The viral replication results in tumor cell
lysis and in the release of tumor antigens in the tumor micro-
environment10. These tumor antigens can be then taken up by
antigen presenting cells (APC) and utilized to direct the immune
response against the rightful target, the cancer cells11.
Ideally, after intratumoral administration of an oncolytic
virus, sufﬁcient amounts of tumor antigens are released and
picked up by dendritic cells (DCs) to present them to T cells
in lymphoid organs, eventually leading up to an anti-tumor
immune response9. However, administration of naked oncolytic
virus often favors the induction of anti-viral over anti-tumor
immunity. To overcome this hurdle, vaccination strategies with
administration of viruses coated with peptides derived from
TAAs have been found to re-direct the immune response
against the tumor and enhance the therapeutic efﬁcacy onco-
lytic viruses12,13.
However, ﬁnding the right peptides to attach on the virus
surface is a complex process that involves screening of the tumor
peptides, ﬁshing out from wide pools of candidates to create the
perfect recipe to precisely and promptly activate pools of T cells
against the target cells. Moreover, peptides selection is not always
possible and the current state-of-the-art technology does not
allow scientists and clinicians to have clear indications on which
epitopes to use and from which proteins. Thereby, new and
efﬁcient approaches are needed to develop the best tools in order
to exploit the efﬁcacy and precision of immunotherapies.
Here, we seek to develop a technology to equip an oncolytic
adenovirus with the pool of antigens, mirroring the tumor mass,
leading to the creation of a viral nanoparticle (Extra conditionally
replicating adenoviruses, ExtraCRAd). The ﬁrst step involves the
extraction of cell membrane from well-characterized cancer cell
lines, followed by coating the virus with the cell membrane
through a membrane extrusion process14. This technology shows
signiﬁcant results in slowing tumor growth down, activating
speciﬁc anti-tumoral response in both therapeutic and vaccina-
tion set-up in different murine tumor models.
Results
Generation and characterization of ExtraCRAd. Firstly, we
sought out to conﬁrm the successful encapsulation of the onco-
lytic virus within the cancer cell membrane, as hypothesize in
Fig. 1. To this end, the biohybrid viral nanoparticle ExtraCRAd
was imaged by cryo-transmission electron microscopy (TEM). As
shown in Fig. 2a, the co-extrusion of virus and cancer cell
membrane resulted in an artiﬁcially enveloped virus (Fig. 2a, c).
The extrusion process produced both individually enveloped and
groups of viruses enveloped within one membrane vesicle. Nano-
tracking analysis (NTA) served to investigate the formation of
new populations of particles when the membranes were com-
bined with the virus (Fig. 2b, c). This conﬁrmed the qualitative
results of the cryo-TEM. As shown in Fig. 2b, bare viruses are
characterized by a size of 107.0 ± 6.1 nm, deﬁned by one single
peak, signal of a homogenous particles population. As for the cell
membrane vesicles, they resulted slightly smaller compared to the
virus particles, with a diameter of 92.8 ± 0.5 nm, retaining high
homogeneity. Finally, ExtraCRAd showed a consistent population
with size of 117.7 ± 0.8 nm, representing a single viral particle
enveloped within the 10 nm cell membrane layer15. However,
NTA analysis (presented in detail in Supplementary Fig. 1) also
revealed the presence of several peaks corresponding to the
formation of populations characterized by bigger size; we hypo-
thesize that these populations correspond to aggregates of viral
particles enveloped by a single membrane (as evident also from
the cryo-TEM pictures) formed due to the pore size of the
membrane selected for the extrusion (800 nm). This pore size was
initially chosen to avoid any harm to the viral particles during the
process.
Furthermore, the NTA analysis enabled us to quantify the
amount of particles in the different samples (adenovirus particles,
cell membrane vesicles, and ExtraCRAd); the number of particles
produced by the lysis of 3 × 106 cells, followed by ultracentrifuga-
tion and extrusion is 40-fold (vesicles) and tenfold (ExtraCRAd)
higher than the number of viral particles (Fig. 2c). The signiﬁcant
decrease in the number of particles between the sample of cell
membranes alone and ExtraCRAd is indicative of the membrane
assembling process around the viral particles occurring during the
extrusion process, with the creation of a stable ﬁnal product. The
difference between the number of events recorded in the virus
sample and in ExtraCRAd is however not statistically signiﬁcant.
To investigate the effect of different physiological buffers on
the extrusion process, dynamic light scattering (DLS) and
electrophoretic light scattering (ELS) were employed to check
size of the virus (Fig. 2d), homogeneity and surface charge
(polydispersity index (PdI) and zeta (ζ)-potential values for the
samples in physiological buffers are presented in Supplementary
Fig. 2b, c). The average hydrodynamic diameter for ExtraCRAd
extruded in isotonic glucose (5.4%) isotonic solution or in saline
0.9% solution ranges, respectively, from 526 ± 39 nm for saline to
microsized aggregates (1504 ± 85 nm) for glucose, highlighting
the unsuitability of these buffers in the extrusion process
(Supplementary Fig. 2a). As for phosphate-buffered saline
(PBS), the initial size of the virus not coated (115.8 ± 0.8 nm)
increases after extrusion with the cell membrane to 122.9 ± 0.8
nm. We also extruded the samples in ultrapure (milli-Q) water,
where the virus before extrusion presented an average hydro-
dynamic diameter of 133.6 ± 2.9 nm, which increased after
extrusion to 140.9 ± 2.7 nm. As for the homogeneity of the
samples, as reported in Supplementary Fig. 2b, the extrusion in
glucose (5.4%) resulted in a widely polydisperse sample
(PdI 0.439 ± 0.03), while for the other extrusion buffer assessed
the sample produced retained a high homogeneity, as indicated
by the values of PdI below 0.2 (0.206 for ultrapure water, 0.140
for PBS, and 0.195 for saline solution). Moreover, the initial
population of virus, as highlighted also in the NTA analysis, was
highly monodisperse, with PdI of 0.152 when dispersed in
ultrapure water and 0.084 when suspended in PBS. The surface
charge of ExtraCRAd was highly negative (ranging from −13 to
−22 mV) for the samples extruded in ultrapure water, PBS, and
saline solution, while it was less negative (−7.9 mV) for samples
extruded in glucose (5.4%; Supplementary Fig. 2c).
Finally, in order to evaluate the feasibility of the cell membrane
as antigenic source, we analyzed ExtraCRAd (using virus and
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extruded cell membrane vesicles as controls) by proteomics
approach. As displayed in Fig. 2e, a sample of virus presents only
seven human proteins associated with ribosomes, and possibly
derived from the production of the virus in human cell lines or
from other contaminations, derived from the production
equipment. Most importantly, both extruded membrane vesicles
and ExtraCRAd displayed a similar number of total hits, with 125
proteins (corresponding to 94.7% of the total protein hits in
membranes and 88.1% for ExtraCRAd) in common between the
two samples. Moreover, as presented in Supplementary Fig. 3,
based on subsequent bioinformatics of the mass spectrometry
results, some of the proteins recovered on the cell membrane are
involved in the presentation of antigens (major histocompat-
ibility, MHC, complexes) (Supplementary Fig. 4). The most
abundant protein recovered was the major vault protein (MVP),
implicated in various drug resistance mechanisms in cancer
cells16. These results conﬁrmed that the virus was effectively
encapsulated within a layer of cell membrane. Furthermore, the
presence of protein hits on the cell membrane wrapped around
the virus remained similar as to a control extruded cell
membrane. We hypothesize that these proteins could be
considered tumor-antigens and they could eventually direct the
anti-tumor immune response.
Based on the physical characterization described above, we
hypothesized the structure of ExtraCRAd as shown in Fig. 2f,
where a core constituted of one (or several) viral particles is
enveloped by a lipid bilayer derived from the cell membrane of
cancer cells. This membrane brings along membrane proteins
that will acts as antigens, priming the immune system against
the tumor.
ExtraCRAd displays increased infectivity in relevant cancer
cells. After successfully proving the encapsulation of the virus
within the membrane, we investigated whether the extrusion
process resulted in any damage to viral infectivity. The infectious
titer of adenovirus decreased from 2.24 × 1011 pfu/ml for naive
virus to 1.92 × 1011 pfu/ml after extrusion, equivalent to a 15%
decrease in infectivity. We then evaluated the functionality of the
virus after the coating process with the cell membrane. We
compared the naked oncolytic adenovirus to ExtraCRAd in cell
viability assay using two human cancer cell lines, A549 and
SKOV-3-Luc, characterized by different levels of expression of the
human Coxsackie and Adenovirus receptor (CAR). A549 exhibits
a high level of CAR receptors; after 2 h of infection, followed by
3 days of incubation, we obtained a statistically signiﬁcant dif-
ference between cells infected with naked adenovirus or Extra-
CRAd (Fig. 3a). The infection with ExtraCRAd at 100 and 10
multiplicity of infection (MOI) results in a 90% reduction in the
viability (compared to a 60% reduction at 100 MOI and 10%
reduction at 10 MOI for the naked virus). The increased cyto-
pathic effect of ExtraCRAd is seen also at lower MOI (1), with a
50% decrease in the cell viability. In contrast, SKOV-3 cell line is
characterized by a low amount of CAR receptors that hinders the
entry of the virus within the cell. This is reﬂected by the lower
killing activity of the naked adenovirus, as shown in Fig. 3b
(blue line). However, when ExtraCRAd is administrated to the
cells, the 3-day viability of SKOV-3 cells is reduced by 25%
compared to the naked virus. These results suggest that there are
differences in the uptake mechanism between naked and coated
virus (i.e., the property of the cancer membrane to fuse with the
membrane of the cells and deliver the virus intracellularly over-
coming the need for a CAR receptor and the uptake of Extra-
CRAd as a nanoparticle through endocytosis)17. As shown in
Supplementary Fig. 5 ExtraCRAd increased the viral infectivity
signiﬁcantly in both low- and high-CAR cell lines bypassing the
standard mechanism of infection through the viral receptor.
We then evaluated the oncolysis in a more complex model, by
implanting human xenografts in nude mice. The results presented
in Fig. 3c show statistically signiﬁcant increase in the oncolysis of
established human xenograft tumors after a single treatment at
day 15 with ExtraCRAd when compared to the naked adenovirus.
This difference is accentuated with the second administration of
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Fig. 1 ExtraCRAd, production and treatment. Tumor cells (a) were cultured and engrafted into mouse model (b1). We employed the same cell line to
extract the cell membrane: cells were lysed, tumor membrane isolated and mixed with an oncolytic adenovirus serotype 5, with a 24-base-pairs deletion,
carrying -CpG islands (i.e., A5-Δ24-CpG)60 (b2). Through the extrusion process the virus was artiﬁcially wrapped with the cancer cell membrane to obtain
ExtraCRAd (c). Finally, established tumors were treated with multiple intratumoral injections of ExtraCRAd (d). The petri dish, mice and syringes images
are taken from Servier Medical Art, under Creative Commons Attribution 3.0 Unported License.
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the treatment at day 25. More importantly, these results are in
agreement with the in vitro killing assays, highlighting the
promising oncolytic effect of the formulation in more complex
conditions (3D vascularized tumor model).
In conclusion, this set of experiments proved that the
encapsulation process does not hinder virus infectivity and killing
ability, whereas it increases the infectivity in a CAR-independent
manner.
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Fig. 2 Physical characterization of ExtraCRAd. A Cryo-transmission electron microscopy (TEM) images of a virus, b lipid cancer membrane vesicles, and
c ExtraCRAd. B16.OVA cell line was employed as source for the membrane. Scale bar: 500 nm. The insets on the right were magniﬁed ten times compared
to the original image. b Nano-tracking analysis (NTA) showing the size distribution of the samples. The size distribution is expressed as percentage of the
total population. The size intervals are presented on the right. c NTA quantiﬁcation of the concentration of viral particles or nanosized vesicles in the
samples. The results are presented as number × 106 vesicles per ml. The data were analyzed by two-way ANOVA followed by Tukey’s post-test. The level
of statistical signiﬁcance was set at probability level ****p < 0.0001. d Dynamic light scattering (DLS) size analysis of the system in different extrusion
buffers. The results are presented as mean ± s.d. (n= 3). e Venn-diagram representing the results retrieved from the mass spectrometry analysis of the
samples (virus, ExtraCRAd produced with membranes derived from human lung cancer A549 cells and extruded membrane vesicles from A549 cells).
The Venn size reﬂects the total number of unique proteoforms for each sample, with the shared proteins presented in the intersection of the diagrams.
f Graphic illustration of an ExtraCRAd: adenovirus 5-D24-CpG (light blue), lipid membrane (orange), and proteins (light green). The error bars indicate s.d.
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ExtraCRAd cellular internalization mechanisms. One of the
disadvantages of oncolytic adenoviruses is their need for the CAR
receptor in order to infect cancer cells18. This may lead to loss of
efﬁcacy of the therapy due to downregulation of the CAR
receptor by the tumor cells19,20. On the contrary, generally the
uptake of nanoparticles is CAR receptor-independent and is
mediated by different mechanisms according to the size,
surface charge, shape, and presence of a protein corona21–23. The
uptake mechanisms can be passive (diffusion of substances
through the cytoplasmic membrane) or active (phagocytosis;
receptor-mediated endocytosis; micropinocytosis)24. Given the
hybrid nature of ExtraCRAd, we sought to investigate its uptake
mechanism. We evaluated if ExtraCRAd entered preferably
through receptor or following the behavior of a lipid structure
fusing with the cancer cell membrane. Firstly, we investigated the
kinetic of the uptake (Fig. 3d) by infecting A549 cells with
ExtraCRAd or with the naked virus for 1, 2, or 3 h before
removing the sample in the supernatant. The cells were then
incubated overnight to allow the expression of the luciferase
transgene and lysed after 24 h, quantifying the luminescence
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Fig. 3 ExtraCRAd mechanism of infectivity, transduction, and antibody resistance. Infectivity assay on a A549 (high-CAR) and b SKOV-3 (low-CAR) cell
lines. Both the cell lines were infected with ExtraCRAd (red) or the naked virus (blue). Cell viability at 3 days was evaluated by the MTS assay. The data are
presented as mean ± s.d. (n= 3). c In vivo assessment of the oncolytic efﬁcacy of the naked virus compared to ExtraCRAd in A549 xenografts in nude
mice. The mice were injected subcutaneously with 5 × 106 cells per ﬂank. The treatments (mock, PBS; CCM, cell membrane vesicles derived from 3 × 106
A549 cells; Virus, 1 × 109 viral particles; ExtraCRAd, 1 × 109 viral particles co-extruded with 3 × 106 A549 cells) were injected at day 15 and at day 25 post
tumor implantation. The data are presented as mean ± SEM (n≥ 8) and were analyzed by two-way ANOVA followed by Tukey’s post-test. Error bars
represents SEM. The levels of statistical signiﬁcance were set at probabilities **p < 0.01 and ***p < 0.001. d Uptake kinetic study: the differences in the
uptake kinetic were assessed by infecting A549 cells with ExtraCRAd or naked virus (adenovirus modiﬁed to express luciferase) for 1, 2, or 3 h, and by 24 h
incubation to allow the expression of luciferase. The data are presented as mean ± s.d. (n≥ 3) with the dot plot of the single replicates. Unpaired t-test was
used to assess statistical signiﬁcance. Neutralizing antibodies assay performed with e plasma from pre-immunized mice and f with anti-adenovirus
serotype 5 antibody. ExtraCRAd and the naked virus were pre-incubated with the serum of pre-immunized mice at different dilutions (e) or with the
antibody diluted 1:2 000 (f) for 60min before the infection. A549 cells were infected with ExtraCRAd or the naked virus for 2 h, followed by 24 h of
incubation, before being lysed. The data are presented as mean ± s.d. (n≥ 3). Analysis with a two-way ANOVA, followed by Fisher LSD post-test was
performed in f, while a two-way ANOVA, followed by Sidak post-test, was used to assess statistical signiﬁcance in all the experiments, unless otherwise
speciﬁed. Levels of signiﬁcance were set at *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Error bars represent s.d., unless otherwise speciﬁed.
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produced. ExtraCRAd displayed increased entry in the cells after
2 and 3 h infection when compared with the naked virus. Then,
we elucidated the uptake mechanism (either active or passive) by
evaluating the differences between ExtraCRAd and control virus
at low temperature (on ice) (Supplementary Fig. 6a). No statis-
tically signiﬁcant difference was found between ExtraCRAd and
the virus. Taking into account the size of the particles (around
100 nm), these results suggest an active uptake process and not a
passive fusion of the system with the cell membrane25,26.
Thereby, chlorpromazine and sucrose were chosen as suitable
inhibitors to elucidate a difference in the uptake of virus or
ExtraCRAd: both the compounds act on clathrin/caveolin medi-
ated endocytosis21. The incubation with sucrose resulted in
comparable reduction of the uptake between coated and uncoated
virus (Supplementary Fig. 6b), while, for chlopromazine, the
inhibition of the uptake was higher for ExtraCRAd (Supple-
mentary Fig. 6c). These results suggest that ExtraCRAd relies on a
clathrin-mediated endocytosis much more than the naked ade-
noviruses, due to the different size, composition, and surface
properties of ExtraCRAd26.
Another downside associated with the clinical use of oncolytic
viruses is the high prevalence of neutralizing antibodies against
several serotypes of adenoviruses in the human population27,28.
We hypothesized that the coating of the viral capsid with cell
membranes could shield the virus from neutralizing antibodies, as
nanoparticles coated with red blood cell membrane have shown
increased circulation time29. Firstly, we tested this hypothesis by
studying the inhibition of ExtraCRAd infectivity in presence of
serum from mice immunized with adenovirus (1 month prior to
sacriﬁce by injecting subcutaneously 1 × 109 viral particles, once a
week for 4 weeks). Serum was then isolated and used as source of
adenovirus neutralizing antibodies. As shown in Fig. 3e, the
extrusion process with cell membrane could only shield the virus
at highest concentrations. To eliminate any inﬂuence by plasma
proteins, we further investigated the shielding effect using an
anti-hexon monoclonal antibody (Fig. 3f). ExtraCRAd effectively
hid the virus from the monoclonal anti-hexon antibody, at the
highest viral concentration tested, as testiﬁed by the increased
expression of luciferase.
In conclusion, we demonstrated the independence of Extra-
CRAd uptake from CAR receptors and the protective effect
offered by the cell membrane towards neutralizing antibodies.
These results showed an increased infectivity and efﬁcacy of the
virus in vitro when wrapped into the cancer cell membrane.
ExtraCRAd controls tumor growth in different mouse tumors.
After the characterization of the structure of ExtraCRAd and its
mode of action in vitro, we proceeded to assess the efﬁcacy of
ExtraCRAd in murine models of melanoma and lung cancer
in vivo. To this end, B16.OVA, B16.F10, and LL/2 murine cancer
cells were injected in the right ﬂank of C57BL/6 mice to establish
subcutaneous tumor models (n= 8 mice per group, one tumor
per mouse). The treatment schedule was performed according
to the following protocol: for B16.OVA, intratumoral injections
(n= 4, injection per tumor) were performed every 2 days, starting
from day 8 after the tumor inoculation; as for B16F10, given its
aggressiveness and fast tumor growth, the ﬁrst injection was
performed on day 6 after tumor inoculation, keeping the same
treatment schedule (4 injections administered every 2 days); for
LL/2, the ﬁrst injection was performed on day 8 after tumor
implantation, following the same scheme (four injections every
2 days). The efﬁcacy of ExtraCRAd in the treatment of the tumor
models is presented in Fig. 4. The mean tumor growth curves for
B16.OVA are shown in Fig. 4a, B16.F10 is reported in Fig. 4b and
LL/2 in Fig. 4c. In all three the tumor models, the treatment
with ExtraCRAd signiﬁcantly slowed down the progression of
the tumors when compared to virus alone, virus mixed with
membranes and ExtraCRAd wrapped with a mismatched cell
membrane. The single tumor growth curves for the three models
are presented in Supplementary Fig. 7 in supporting information.
In the B16.OVA model, the controls (virus and membranes
mixed, but not extruded, and membrane only) groups showed
only 33% of responders, while in the more aggressive B16.F10
model the effect of mix and virus was even more limited (12.5%
and 28%, respectively). As for the LL/2 model, the membrane and
virus controls did not affect the tumor growth in any of the
animals; the mix of membranes and virus could control the
growth in 40% of the animals. However, these results highlight
the potential efﬁcacy of the single components of ExtraCRAd
(virus as an adjuvant and tumor lysate as the source of antigens)
in immunogenic tumors (melanoma) while only the mix of the
two components was partially effective in the lung model. Strik-
ingly, homologous ExtraCRAd treatment signiﬁcantly controlled
the tumor growth in all tumor models. In the B16.OVA model, all
the mice treated with ExtraCRAd responded to the therapy sig-
niﬁcantly better than all the other groups. In B16.F10 model,
62.5% of the animals responded to the treatment. In LL/2 tumor
model, homologous ExtraCRAd was able to control the tumor
growth in all the animals treated, while ExtraCRAd formulated
with a heterologous cell membrane derived from a mouse bladder
cancer cell line MB49 could affect the tumor growth in only
half of the animal cohort. Thereby, we showed that wrapping
an oncolytic virus with a tumor cell membrane signiﬁcantly
enhances the virus efﬁcacy in several tumor models. Most
importantly, we proved that the highest efﬁcacy is achieved when
the virus is coated with homologous, tumor matched, cell
membrane.
ExtraCRAd mediates speciﬁc anti-tumor response in B16.
OVA. In order to elucidate the mechanism of action of Extra-
CRAd, tumors and lymphoid organs from the experiments
described above, were harvested to perform immunological ana-
lyses. As presented in Fig. 5a, the study of the immunological
proﬁle in the tumor microenvironment (B16.OVA model)
showed an increased presence of dendritic cells cross-presenting
the tumor-speciﬁc antigen SIINFEKL on their surface, resulting
in an increase in the potential priming of the effector T cells.
Moreover, the analysis of the tumor microenvironment high-
lighted also an increased number of OVA-speciﬁc CD8+ T cells
in the ExtraCRAd group compared to mock, virus, membrane,
and mix groups (Fig. 5b). The majority of these cells were pre-
senting PD-1 receptor expressed on their surface, which suggest
the activation of the T-cell following the stimulation of T-cell
receptors (Fig. 5c)30. However, OVA-speciﬁc T cells represented
only a small portion of the experienced T cells, indicating that
ExtraCRAd therapy could potentially elicit the activation of a
variety of different T cells. In fact, the total pool of CD8+ T cells
showed a more antigen-experienced proﬁle due to the upregula-
tion of PD-1+ on their surface (Fig. 5d) in mice treated with
ExtraCRAd. Interestingly, we observed an increase in the antigen-
experienced T cells also in the mix control group, highlighting the
importance of the virus as adjuvant and the cell membrane
vesicles as sources of the tumor antigens. As previously described
in the work of Capasso et al.12, a virus bearing cancer-speciﬁc
peptide represents an efﬁcient strategy to train the immune
system in mounting a cancer-speciﬁc response employing an
oncolytic virus as adjuvant. We implemented such technology by
adopting the properties of a tumor lysate to reach a broader, but
still cancer-speciﬁc effect. Tumor lysate elicits different beneﬁcial
mechanism in cancer patients by inducing rapid (24–48 h) and
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committed maturation to Th1/Th17 polarizing DCs7 and
eradicating tumor in murine models when combined with CpG
oligonucleotides31. Dendritic cells are then able to prime multiple
pools of T-cells favoring the Th1 lineage32. To capitalize on these
previous ﬁndings, ExtraCRAd was designed to include tumor
lysate, viral CpG and oncolytic properties in a single vaccine
particle, therefore providing an enhanced version of cell-lysate-
based vaccines. Importantly, our platform allows for co-delivery
antigens and adjuvants into the same APC, which has been
shown to be critical in terms of inducing sufﬁcient CD8 T-cell
responses33–36.
ExtraCRAd increases DCs and T-cells in aggressive melanoma.
The tumors and spleens belonging to mice inoculated with B16.
F10 cells were collected, processed into single-cells suspension,
and labelled with anti-(a)CD8 for T-cells, aCD19 for B-cells,
gp100 and TRP-2 pentamers for tumor-speciﬁc T cells, aPD1 for
2500
B16.OVA
B16F10
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
a
b
c
2000
1500
1000
500
0
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
Tu
m
o
r 
vo
lu
m
e 
(m
m3
)
2000
1500
1000
500
0
1000
800
600
400
200
0
0 5 10 15 20 25 30
0 6 8 10 12 14 16 18
0 10 12 14 16
Days
Days
Days
LL/2
18 20 22
Mock
Membrane
Mix
Virus
ExtraCRAd
Mock
Membrane
Mix
Virus
ExtraCRAd
Mock
Membrane
Mix
Virus
ExtraCRAd MB49
ExtraCRAd LL2
24
Fig. 4 Efﬁcacy of the treatment with ExtraCRAd in three mouse tumor models. Median tumor growth curves for a B16.OVA, b B16.F10, and c LL/2. In the
median curves the data are presented as mean ± s.d (n≥ 7). Error bars represent s.d. The results were analyzed with a two-way ANOVA, followed by Tukey’s
(a, b) and Dunnet’s (c) post-test comparison, and the levels of signiﬁcance were set at the probabilities of *p < 0.05, **p< 0.01, ***p < 0.001, ****p < 0.0001.
Mice were injected every second day four times starting at day 8 post-injection for B16.OVA and LL/2 and at day 6 post-injection for B16.F10.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13744-8 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5747 | https://doi.org/10.1038/s41467-019-13744-8 |www.nature.com/naturecommunications 7
antigen-experienced T-cells, aCD68 for macrophages identiﬁca-
tion, aCD11c for dendritic cells, and aCD370 for cross-presenting
activated dendritic cells.
Tumors treated with ExtraCRAd showed an increase in the
number of tumor-speciﬁc T cells, as in the number of PD-1+
T cells (Fig. 5f–h). All these results conﬁrmed our previous
ﬁndings in the B16.OVA model (Fig. 5a–d). We also recorded an
increase in the number of dendritic cells (Fig. 5e), macrophages
(Supplementary Fig. 8a) and total CD8+ T cells (Supplementary
Fig. 8b) within the tumor microenvironment, showing a complex
and general interaction of different immunological effector cells.
Interestingly, the amount of CD8+ and CD11c+ cells increased in
the spleens of mice treated with ExtraCRAd (Supplementary
Fig. 9a, c). A further investigation with CD370 marker revealed
an augmented cross-presentation activity of the DCs in the spleen
(Supplementary Fig. 9b) and in the number of tumor-speciﬁc
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T cells (Supplementary Fig. 9d). Thus, we hypothesize that
ExtraCRAd elicits a broader response, including tumor-speciﬁc
and non-speciﬁc immune response37.
ExtraCRAd primes a strong immunity in a solid tumor model.
The efﬁcacy of immunotherapies is greater in loose, permeable,
tumors (e.g., melanoma) when compared to solid tumors due to
the physical hindrance to the migration of immune cells within
the tumor microenvironment38–40. Thereby, after having eval-
uated the efﬁcacy of ExtraCRAd into a solid tumor model (LL/2
lung cancer), we investigated the immune contexture in the
tumor microenvironment, spleen, and draining lymph nodes. As
reported in Fig. 5i, j, the treatment with ExtraCRAd does not
result into an increase in the fraction of dendritic cells or mac-
rophages in the tumor microenvironment. However, the tumors
treated with homologous ExtraCRAd are inﬁltrated by a statis-
tically signiﬁcant percentage of both CD4+ and CD8+ T-cells
(Fig. 5k, l). These changes are associated with a local immune
response as suggested by the immunological proﬁle of the spleen
(Supplementary Fig. 10), which displays no differences between
the treatments, compared to the immune contexture of the
draining lymph node (Supplementary Fig. 11). In particular,
the draining lymph nodes of animals treated with homologous
ExtraCRAd present an increased population of APCs (Supple-
mentary Fig. 10a), together with a signiﬁcant increase in the
CD8+ T-cell population (Supplementary Fig. 10c). These results
suggest that ExtraCRAd can induce anti-tumor immunity by
simultaneously providing both antigenic material and immu-
nostimulatory signal to DCs, both of which are needed for efﬁ-
cient T-cell priming to occur in the draining lymph nodes.
ExtraCRAd efﬁcacy as preventive vaccination. Lastly, we
investigated whether a preventive vaccination scheme with
ExtraCRAd would protect against tumor challenge, control the
tumor growth and affect the overall long-term survival. The
pre-immunization set-up allows to evaluate the efﬁcacy of the
formulation in creating a memory immune response without
confounding factors, including the release of Damage-associated
molecular pattern (DAMPs) in the tumor microenvironment
following each administration of the therapy41. To this end, we
vaccinated the animals for a total of three times before challen-
ging them with CMT64.OVA or B16F10 tumor cells. As reported
in Fig. 6a, b, the immunization with ExtraCRAd wrapped with
homologous tumor-matching membranes (ExtraCRAd CMT64.
OVA in the CMT64.OVA model and ExtraCRAd B16.F10 in the
B16.F10 model) prolongs the overall survival on the animals with
>50% of the animals still alive at day 40 after tumor engraftment
(CMT64.OVA) and at day 28 after tumor implantation in the
B16.F10 model. Both the control of naked virus and ExtraCRAd
wrapped in a heterologous miss-matched tumor membrane do
not affect the overall survival, with none (CMT64.OVA) or one
animal (B16F10) still alive at the end of the experiment.
The survival data is reﬂected in the tumor growth graphs,
where homologous ExtraCRAd was able to signiﬁcantly inhibit
tumor growth compared to other treatment groups, as presented
in Fig. 6c, d. In the CMT64.OVA model, the vaccination with
naked virus or miss-matched ExtraCRAd does not have a
signiﬁcant effect on the tumor growth, while the homologous
ExtraCRAd statistically slowed the tumor growth rate. More
interestingly, in the aggressive melanoma model B16.F10 we
observed a partial control over the tumor growth mediated by the
vaccination with naked virus and with the heterologous
ExtraCRAd compared to the mock group. Nevertheless, homo-
logous ExtraCRAd vaccination was found to be the most effective
regimen in these tumor challenge models. Overall, these results
indicate that a vaccination scheme with ExtraCRAd wrapped in a
matched membrane is required for induction of tumor-speciﬁc
immunity and for the therapeutic and/or preventive efﬁcacy,
leading to sustained tumor growth control.
Discussion
The recent discoveries in cancer immunotherapy contributed to a
shift in the paradigm of cancer treatment from a preconditioning
wiping out the immune system before the administration of
chemotherapeutics to the exploiting of the immune system’s
ability for the precise targeting and killing of cancer cells42. The
application of immune check-point inhibitors in the clinics
contributed to this revolution and, at the same time, highlighted
the limits of cancer immunotherapy43. There is a urgent need for
the discovery and delivery of tumor neoantigens to prime more
efﬁciently the patient’s immune system. A recent compromise
suggests the use of membranes derived from cancer cells as crude
sources of neoantigens, especially in the case of highly mutagenic
tumors. The isolation and further processing of this biological
material are relatively easy making them suitable for applications
in the development of cancer vaccines44.
In parallel, there is a high demand for potent and safe cancer
vaccines able to effectively stimulate antigen presenting cells and
break the tumor-induced immunotolerance45. The development
of virus nanoparticles carrying cancer moieties represent a very
versatile technology with wide applicability to different kind of
cancers to stimulate an immune response. Virus-like particles
have been widely employed as adjuvants in the formulation of
cancer vaccines46, while oncolytic virus are currently being re-
evaluated as powerful vaccines shaped by millennia of co-
existence with the immune system, with less focus on their
oncolytic efﬁcacy47.
Fig. 5 Immunological analyses of the tumor microenvironment. B16.OVA a Percentage of dendritic cells cross-presenting OVA (SIINFEKL) in the context
of MHC class I in the tumor microenvironment, b OVA-speciﬁc, c OVA-speciﬁc antigen-experienced, and d antigen-experienced T cells in the tumor
microenvironment. The number of T cells was normalized by the tumor volume. Mix identiﬁes a treatment composed of cell membrane vesicles just mixed
with adenovirus without extrusion. The results are presented as mean ± s.d (n≥ 3) and the dot plot of the single replicates. The data were analyzed with a
two-way ANOVA, followed by Dunnet (a–c) or Tukey (d) post-test comparison. The levels of signiﬁcance were set at the probabilities of *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001. B16F10 e CD11c+ dendritic cells percentage in the tumor microenvironment and f gp100 and g TRP2 pentamer-speciﬁc
T-cells, identifying the CD8+ tumor-speciﬁc T-cells in the tumor microenvironment. h Antigen-experienced T-cells measured by the expression of PD-1 on
T-cells. Mix identiﬁes a treatment composed of cell membrane vesicles just mixed with adenovirus without extrusion. The data are presented as mean ± s.d
(n≥ 7), together with the dot plot of the single value. The data were analyzed with two-way ANOVA, followed by Fisher LSD post-test. The levels of
signiﬁcance were set at the probabilities of *p < 0.05, **p < 0.01. LL/2 i Percentage of CD11c+ dendritic cells in the tumor microenvironment in the LL/2
model. j Percentage of CD68+ macrophages. k Percentage of CD4+ and l CD8+ T-cells in the tumor microenvironment. Mix identiﬁes a treatment
composed of cell membrane vesicles just mixed with adenovirus without extrusion. The data are presented as mean ± s.d. (n= 4) and were analyzed by
two-way ANOVA, followed by Dunnet’s post-test. The levels of signiﬁcance were set at the probabilities of *p < 0.05 and **p < 0.01. The error bars
represent s.d.
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In this work, we develop a method to coat an oncolytic virus
with a cancer cell membrane (ExtraCRAd) and we provide evi-
dence of its efﬁcacy in regulating the tumor growth in different
murine cancer models. We prove how the coating of a virus by
extruding a cancer cell membrane on its surface is beneﬁcial and
exhibits synergistic effects of its components, carrying a wider
spectrum of activity as cancer vaccine. Compared to other type of
cancer vaccinations, such as peptides vaccine or simply the use of
naked oncolytic virus, ExtraCRAd brings the advantage to
combine in the same particle the adjuvant (virus) and the anti-
gens (tumor-associated proteins). This might lead to a more
pronounced immune response without the need of necessarily
knowing the associated tumor antigens. We observe advantages
over the single components both in vitro and in vivo. The viral
transfection is signiﬁcantly increased when the virus is wrapped
in the cancer membrane, implying an uptake mechanism dif-
ferent from the CAR-mediated one of the naked virus and
resulting in increased viral infection also for CAR-negative cell
lines. This ﬁnding is indeed well in line also with other
approaches where adenovectors have been incapsulated in lipo-
somes48–50. In a more clinically relevant tumor model, con-
stituted by high-CAR human cancer cells implanted into nude
mice, ExtraCRAd outperformed the naked virus in controlling
the tumor growth with a purely oncolytic effect, suggesting again
that the entry of the wrapped virus does not only depends on the
expression of the CAR receptor but it can use different
mechanisms that might increase the efﬁcacy of the virus in
absence of the immune system. Furthermore, the technology
contributed to partially shield the virus from neutralizing anti-
bodies. This is a very interesting observation that might open up
a different use and route of administration for this nanovaccine
rather than intratumoral administration. In fact, neutralizing
antibodies have been a difﬁcult obstacle to overcome in classical
gene therapy approaches where viral vectors are delivered
intravenously and are expected to target a speciﬁc tissue51–53. In
the context of oncolytic viruses, and even more in oncolytic
cancer vaccines, the interest for neutralizing antibodies has
diminished as very often these vaccines are almost exclusively
given by intratumoral administration54,55. Our approach shows
potential in eliciting the adaptive immune system increasing the
number of both macrophages and dendritic cells, most of them
activated to present tumor antigens, and later, cancer-speciﬁc
repertoire to ﬁght the cancer itself. This is in line with what
observed with similar approaches where similar immunological
endpoint have been observed12,56,57. In addition and differently
from other works, we proved the efﬁcacy of a preventive vacci-
nation scheme with tumor-matched ExtraCRAd in prolonging
the overall survival and in controlling the tumor growth in pre-
immunization experiments. The tumor type matched membrane
viral particle shows longer survival and efﬁcacy in slowing down
the tumor growth while the non-matched one does not provide a
general advantage in protecting against the tumor. These results
indicate that the vaccination efﬁcacy is not dependent on the
technology but on the need for speciﬁc tumor-matched antigens
over ExtraCRAd. Overall, our results suggest that ExtraCRAd is a
versatile and advanced platform for cancer treatment with an
interesting potential for present and future clinical impact given
its easy tailorability to each patient, choosing a suitable virus and
obtaining cancer cells from biopsy. More investigations to assess
the efﬁcacy of this technology in additional tumor models and
clinical settings are needed.
Methods
Isolation of the cell membrane. We isolated cell membranes from B16.OVA and
B16.F10 murine melanoma cells, LL/2 and CMT64.OVA murine lung cancer,
MB49 murine bladder cancer, human A549 lung cancer, and SKOV-3 ovarian
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Fig. 6 Efﬁcacy of ExtraCRAd in a pre-immunization set-up in melanoma and lung cancer models. a Long-term overall survival of C57BL/6 mice injected
with 7 × 106 CMT64.OVA subcutaneously in the ﬂank. b Long-term overall survival of C57BL/6 mice injected with 1 × 105 B16.F10 cells subcutaneously in
the ﬂank. In both the models, animals were removed from the survival curve upon sacriﬁce. Mice dead for causes not imputable to the tumor growth or
mice still alive at the completion of the study were censored in the survival curves. The data were analyzed with log-rank (Mantel–Cox) curve comparison.
The levels of signiﬁcance were set at *p < 0.05, **p < 0.01, and *** p < 0.001. Mean tumor growth curve (mm3) in c the CMT64.OVA model and d the B16.
F10 model. The data are presented as mean ± SEM (n= 6). The data were analyzed with two-way ANOVA followed by Tukey’s (c) and Fisher’s (d) post
test. The levels of signiﬁcance were set at probabilities of *p < 0.05 and ****p < 0.0001. The error bars represent SEM.
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cancer cells, according to the protocol previously published14,58. B16.OVA cells
were cultured in 10% heat inactivated fetal bovine serum (FBS) in Roswell Park
Memorial Institute (RPMI)−1640 medium supplemented with 1% penicillin-
streptomycin, 1% non-essential amino acids, and 1% L-glutamine. In order to select
the cells positive for OVA, geneticin (G418 Sulfate, Thermo Fisher, USA) was
added to the medium, at a concentration of 5 mg/ml. All the other cell lines were
cultured according to American Type Culture Collection protocols. In order to
retrieve the membrane, the cells were washed with 1 × phosphate buffer
solution–ethylenediaminetetraacetic acid (PBS–EDTA; pH 7.4) solution, and
detached. The cells were centrifuged at 660 × g for 10 min and washed three times
with 1 × PBS (pH 7.4). The cell pellet was resuspended into lysing buffer (20 mM of
TRIS HCl; Sigma-Aldrich, USA; 10 mM of KCl; Sigma-Aldrich, USA; 2 mM of
MgCl2; Sigma-Aldrich, USA; 1 protease inhibitor mini tablet, EDTA free; Pierce,
Thermo Fisher, USA) and pipetted thoroughly. We centrifuged the cells at 3200 × g
for 5 min, collected the supernatant, and repeated the procedure, centrifuging the
cells a second time at 3200 × g for 6 min. We pooled the supernatant and cen-
trifuged it at 21,000 × g for 25 min at+ 4 °C. We then collected the supernatant and
centrifuged it at 45,000 × g for 5 min in a TLA 120.0 rotor in an ultracentrifuge
(Optima Max, Beckmann Coulter, USA) at+ 4 °C. The supernatant was then
discarded, and we resuspended the membranes in 1 × PBS prior to extrusion.
Encapsulation of Ad5D24-CpG virus within cell membrane. ExtraCRAd was
prepared using Ad5-D24-CpG virus together with cell membrane fragments by
extrusion through a polymeric membrane (0.8 µm, Nucleopore Track-Etch
Membrane, Whatman, UK) in an extruder (Avanti Polar Lipids, USA). The virus
and the membranes were resuspended in 1 × PBS solution and extruded 5, 10, 20,
30 times through the membrane. For the ﬁnal formulation, 20 passages were
selected as optimal conditions for the complete encapsulation of the virus within
cell membrane vesicles.
Nano-tracking analyses. Extruded virus, cancer membrane and ExtraCRAd were
analyzed using Nanosight model LM14 (Nanosight) equipped with blue (404 nm,
70 mW) laser and SCMOS camera. The samples were diluted in DPBS and three
60 s videos were recorded using camera level 13. The data was analyzed using NTA
software 3.0 with the detection threshold 5 and screen gain at 10 to track as many
particles as possible with minimal background.
Cryo-transmission electron microscope. About 3 μl of fresh samples were snap
frozen on a carbon-coated copper grid and imaged with JEOL JEM-3200FSC TEM,
with 300 kV ﬁeld emission at different magniﬁcations.
Cell lines. The human lung carcinoma cell line A549, human ovarian adeno-
carcinoma SKOV-3, the mouse melanoma cell line B16.F10, the mouse LL/2 lung
cancer line and the mouse bladder cancer cell line MB49 were purchased from the
American Type Culture Collection (ATCC; Manassas, VA, USA). The cell line B16.
OVA, a mouse melanoma cell line expressing chicken OVA, was kindly provided
by Prof. Richard Vile (Mayo Clinic, Rochester, MN, USA). The lung adenocarci-
noma cell line CMT64.OVA was a kind gift from Florian Kuhnel (Hannover,
Germany). All cell lines were cultured under appropriate conditions and were
routinely tested for mycoplasma contamination.
Preparation of conditionally replicating adenoviruses. All CRAds were gener-
ated, propagated, and characterized using standard protocols, as previously
described59. All viruses used in this study have been previously reported: Ad5D24
is an adenovirus that features a 24-base-pair deletion (Δ24) in the E1A gene, Ad5
Δ24-CpG is a CRAd bearing a CpG-enriched genome in the E3 gene60. Ad5-luc is a
non-replicating adenovirus carrying luciferase transgene61.
Zeta (ζ)-potential and dynamic light scattering analysis. Samples were pre-
pared as described in the previous section. Each sample was then vortexed and
diluted to a ﬁnal volume of 700 ml with sterile milli-Q water adjusted to pH 7.4,
after which the sample was transferred to a polystyrene disposable cuvette to
determine the size of the complexes. Afterward, the sample was recovered from the
cuvette and transferred to a DTS1070 disposable capillary cell (Malvern, Wor-
cestershire, UK) for zeta potential measurements. All measurements were per-
formed at 25 °C with a Zetasizer Nano ZS (Malvern).
Cell viability assay. MTS assay was performed according to the manufacturer’s
protocol (CellTiter 96 AQueous One Solution Cell Proliferation Assay; Promega,
Nacka, Sweden). Spectrophotometric data were acquired with Varioskan LUX
Multimode Reader (Thermo Scientiﬁc, Carlsbad, CA, USA) operated by SkanIt
software. About 10,000 cells were plated in 96-well plate 1-day prior infections.
Three days post-infection cell viability was measured using the CellTiter-Fluor™
Cell Viability Assay (Promega), and a multi-well plate reader (Varioskan LUX;
ThermoLabsystems) was used to determine the ﬂuorescence of the samples.
Transfection assay. A549 cells were infected with Ad5-Luc for 1, 2, and 3 h in 2%
FBS in low-glucose Dulbecco’s modiﬁed Eagle’s medium (DMEM) medium. After
the infection time medium was discarded, cells washed twice with PBS and new
10% FBS in low-glucose DMEM added. After incubation overnight, cells were lysed
with NP40 lysis buffer and luciferase level analyzed by plate reader Varioskan LUX.
Neutralizing antibody assay. Mice were immunized by a single subcutaneous
injection of 1 × 109 viral particles of Adenovirus5 Δ24-CpG. One month later,
animals were sacriﬁced and blood was collected through heart puncture. After
15 min at room temperature blood cloth was removed and vials centrifuged at 4 °C
for serum separation. Serum was then collected and stored at −20 °C. For the NAb
assay, Ad5-LUC virus was incubated for 1 h at 37 °C with serum and further used
to infect cells for 2 h. In vitro assay was performed with monoclonal antibody
against viral hexon protein (Novus Biological, Littleton, CO, USA). Luciferase
expression levels were detected by Varioskan LUX.
Sample preparation for proteomics. Three parallel cell membrane isolations
followed by extrusion and/or encapsulation, were performed as described above
using human lung cancer A549. Samples were solubilized in 0.2% of RapiGest SF
(Waters Inc., Milford, MA, USA), dried in a speed vacuum (Eppendorf Con-
centrator Plus; Eppendorf AG) and resuspended in 50 mM of ammonium bicar-
bonate buffer, pH 7.8 (AMBIC). The protein concentration was determined with a
standard BCA protein assay kit (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
Samples were either diluted further or pipetted directly to a ﬁnal volume of 50 µl in
50 mM of AMBIC, such that the ﬁnal protein amount used for preparation of
tryptic peptides was 7 µg. Tryptic peptides were prepared using Thermo Fisher
Scientiﬁc’s In-Solution Tryptic Digestion and Guanidination Kit according to the
instructions of the manufacturer, but without the guanidination step. After over-
night digestions, formic acid was added to a ﬁnal concentration of 0.1%, incubated
at 37 °C for 45 min, followed by centrifugation at 16,200 × g for 15 min in order to
remove Rapigest SF and particulate debris from the samples.
Liquid chromatography–tandem mass spectrometry. Digested peptides were put
in auto sampler vials and loaded into an Easy-nLC 1200 (Thermo Fisher Scientiﬁc)
coupled to an Orbitrap Fusion MS (Thermo Fisher Scientiﬁc). Chromatographic
separation was carried out in commercially packed C18 columns (Acclaim PepMap
2 mm, 100 Å, 75 mm, 15 cm; Thermo Fisher Scientiﬁc). Peptides were loaded in
buffer A (5% of acetonitrile and 0.1% of formic acid) and eluted with a 1 h linear
gradient from 5 to 30% of buffer B (80% of acetonitrile and 0.1% of formic acid).
Three biological replicates were sequentially injected with two 15-min wash runs
and a 1 h blank run alternated between distinct ‘treatments’. Mass spectra were
acquired using a Top20 data-dependent method with an automatic switch between
full MS and MS/MS (MS2) scans. The Orbitrap analyzer parameters for the full MS
scan were resolution of 120,000 mass range of 350 to 1800 m/z, and AGC target of
4e5 ions, whereas those for MS2 spectra acquisition were resolution of 30,000, AGC
target of 5e4 ions, an isolation window of 2 m/z and dynamic exclusion of 30 s.
Column chromatographic performance was routinely monitored with intermittent
injections of 50 fmol of a commercially available Bovine serum albumin (BSA)
peptide mix (Waters Inc.), as well as evaluating double-wash runs for carryover
peptides.
Data processing. Protein groups identiﬁcation and quantiﬁcation were carried out
within the MaxQuant software, package, v. 1.6.1.062, with a UniProtKB human
FASTA ﬁle containing 86,725 entries to which 245 commonly observed con-
taminants and all reverse sequences were added.
Data analysis. Enrichment analysis and hierarchical clustering were carried out
with Perseus data analysis software v.1.5.6.063. Abundance values were log2
transformed, and protein identiﬁcations classiﬁed as being only identiﬁed by site,
reverse sequences and potential contaminants were ﬁltered out from the main data
frame. Additionally, only identiﬁcations with non-zero intensity values in all three
biological replicates from at least one ‘treatment’ were retained for comparisons.
An intensity value that was less than the lowest intensity value from the entire data
matrix was assigned to the proteins with missing quantiﬁcation values to enable
differential enrichment comparisons via hierarchical clustering.
Pathway analysis. Functional analyses were carried out within the gene ontology
(GO) database using the enrichment analysis tool64.
Animal experiments and ethical permits. All animal experiments were reviewed
and approved by the Experimental Animal Committee of the University of Hel-
sinki and the Provincial Government of Southern Finland. Female 4–6-weeks-old,
C57BL/6JOlaHsd mice were obtained by ENVIGO. Female nude mice (HsdCpb:
NMRI.Foxn1nu) 4–6-weeks-old were obtained by ENVIGO.
In the in vivo investigation of the oncolytic efﬁcacy of ExtraCRAd, human lung
cancer grafts were established into nude mice by injecting 5 × 106 subcutaneously
in both the ﬂanks (two tumors/mouse). The established tumors were treated with
1 × 109 virus particles twice, 15 and 25 day post implantation.
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In the therapeutic vaccination set-up, tumors were established injecting 3 × 105
of B16-OVA murine melanoma cells, 1 × 105 of B16F10 murine melanoma cells, or
1.5 × 105 LL/2 murine lung cancer cells subcutaneously into the right ﬂank of
C57BL/6 mice. 1 × 109 virus particles were injected intratumorally four times every
second day in established tumors starting at day 8 post implantation. At day of
sacriﬁce tumor, spleen, and lymph nodes were collected from each mouse and
frozen in −80 °C, in freezing media (10% of dimethyl sulfoxide media) for further
immunological analyses.
In the pre-immunization set-up, C57BL/6 mice were immunized three times at
days 1, 3, 14 with the equivalent of 1 × 109 virus particles in all the treatments. The
mice were then injected on day 21 with 7 × 106 CMT64.OVA cells or 1 × 105 B16.
F10 cells subcutaneously in the right ﬂank. The tumor growth was measured every
2 days.
Flow cytometry analysis. Flow cytometry analysis was performed using a BD
Accuri 6 plus (BD Biosciences) and analyzed by FlowJo software (Tree Star,
Ashland, OR, USA). Epitope- speciﬁc T cells were studied using MHC Class I
Pentamers (F093-84C-E, ProImmune, Oxford, UK). Other antibodies used inclu-
ded the following: murine Fc block CD16/32 (101320, Biolegend); FITC anti-
mouse CD8 (A5402-3bE, ProImmune); PE/Cy7 anti-mouse CD19 (115520, Bio-
legend), FITC anti-mouse CD11c (117306, Biolegend), APC anti-mouse H-2Kb
bound to SIINFEKL(116619, Biolegend), PE anti-mouse CD370 (143504, Biole-
gend), PE anti-mouse PD-1 (135206, Biolegend), PE anti-mouse CD68 (137013,
Biolegend), APC anti-mouse CD4 (100412, Biolegend). All staining procedures
were performed according to the manufacturer’s recommendations. Gating stra-
tegies are shown in supplementary Fig. 12.
Statistical analyses and correlation models. Statistical analysis was performed
using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA). A detailed
description of the statistical methods used to analyze the data from each experi-
ment can be found in each ﬁgure caption.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the data supporting the ﬁndings of this study are available within the article and
its supplementary information ﬁles and from the corresponding author upon reasonable
request. A reporting summary for this article is available as a Supplementary Information
Files.
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